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Some ligand–receptor couples involve spare receptors, which are apparent when a maximal response
is achieved with only a small fraction of the receptor population occupied. This situation favours cross-
reactions with low-afﬁnity ligands, which may be detrimental for cell signaling. In the case of the
adenosine A2A receptors (A2AR), which have an immunosuppressive effect on lymphocytes through
cAMPproduction, thepresenceof spareA2AR remains tobeestablished.Weexamined the situationusing
patients over-expressing lymphocyte A2AR and an agonist-like mAb to A2AR. We found that maximal
mAb binding and functional response varied among the patients whereas the dissociation constant
and half-maximal effective concentration had similar mean values (0.19 and 0.18 μM, respectively).
Lymphocyte A2AR expression was correlated to plasma adenosine level and A2AR occupation but not
to A2AR response. These results are consistent with a lack of a reserve of functional A2AR on human
lymphocytes as a general rule and suggest that the amount and functional state of the expressed A2AR
determine the maximal level of the lymphocyte response to adenosine.
C© 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. Open access under 
CC BY-NC-ND license.1. Introduction
Adenosine, an endogenous purine nucleoside, acts through four
classes of G protein-coupled receptors (A1R, A2AR, A2BR and A4R) to
exert various physiologic effects [1]. Most of these actions affect car-
diovascular, neuronal and immunecells [2–7]. In lymphocytes, adeno-
sine regulatesmultiple physiologic processes including inﬂammation
[8–14] and congenital defect of adenosine deaminase – an enzyme
that degrades the nucleoside and hence regulates its plasma level –
associated with aberrant signaling through adenosine receptors con-
tributes to the severe combined immunodeﬁciency syndrome [15].
CD4+ and CD8+ T-cells express A2AR, A2BR, and A3R [16–21]. Numer-
ous in vivo and in vitro studies suggest that A2AR selectively inhibit
T-cell receptors of activated T-cells, thereby inhibiting lymphocyte
inﬂammatory activity [18,22–25]. Activation of the A2AR on CD4
+ T-
cells prevents myocardial ischemia–reperfusion injury by inhibiting
the lymphocyte accumulation and activation in the reperfused heart
[26]. A2AR can also prevent Th1/Th2 development [27] as well as T-
cell apoptosis [28]. Finally, it was reported that adenosine producedby regulatory T-cells mediates immune suppression activity through
Abbreviations:A2AR, adenosine A2A receptors; Emax, maximal ligand response; Bmax,
maximal occupation of the receptors; EC50, half-maximal effective concentration; KD,
dissociation constant; NMS, neurally-mediated syncope; APC, adenosine plasma con-
centration; PBMC, peripheral blood mononuclear cells; AU, arbitrary units
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http://dx.doi.org/10.1016/j.fob.2012.11.004A2AR [29,30]. Thus, the study of the expression and function of A2AR
on lymphocytes appears to be of pivotal importance to evaluate their
immuno-regulatory role.
Various ligand–receptor models are available in pharmacology
and may be applicable to agonist–A2AR interactions in order to study
the role of A2AR in lymphocyte regulation. Among them, the spare re-
ceptor theory [31] postulates that a given ligand can exert maximum
biological effect while occupying only a small amount of the avail-
able receptors. Such a reserve of receptors may allow for a response
to low, transient ligand concentrations and low-afﬁnity interactions
which are compatible with several T-cells properties, hence support-
ing the presence of spare receptors for T-cell receptor activation [32].
From a pharmacological point of view, the presence of spare recep-
tors is evidenced if the maximal ligand response (Emax) is obtained at
less than themaximal occupation of the receptors (Bmax). This pattern
is usually determined by comparing the half-maximal effective con-
centration (EC50) that refers to the ligand concentration necessary to
reach 50% of the maximal effect with the dissociation constant (KD)
that refers to the ligand concentration necessary to reach 50% of the
maximal binding. If the EC50 is less than the KD, spare receptors are
existing.
Spare A2AR were reported in cardiac tissue of guinea pig using
an irreversible A2AR antagonist to block receptor response to various
agonists [33]. In other study on mouse T-cells, using gene target-
ing to generate mice lacking one or two alleles of A2AR, the authors
showed that the decrease in the number of A R in thymocytes from2A
A2AR
+/− and A2AR−/− mice versus the A2AR+/+ control mice resulted
Open access under CC BY-NC-ND license.
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pn proportional decrease in the adenosine-induced cAMP and apopto-
is responses of their respective T-cells [34]. No investigations were
onducted on human lymphocyte A2AR expression, occupation and
unction because of some experimental constraints, mainly low A2AR
xpression in normal individuals and lack of efﬁcient ligand to stably
ind to the receptor. Here, we took advantage of Adonis, an agonist-
ike mAb which steadily binds to an extra-cellular part of the A2AR
35], to investigate the presence of a reserve of A2AR in peripheral
ymphocytes of patients with neurally-mediated syncope (NMS) who
enerally display high adenosine plasma concentrations (APC) and
ncreased lymphocyte A2AR expressions [36–38].
. Materials and methods
.1. Selection of patients
Ten patients with clinical symptoms of NMS [38] were enrolled.
MS patients were chosen because they frequently exhibit high APC
36,39] associated with high expression levels of A2AR on peripheral
ymphocytes [37], which was found to mirror the increase in A2AR
xpression on disease target organs [40]. This study was conducted
n compliance with the principles of the Declaration of Helsinki and
pproved by the Ethics Committee for Human Research of our uni-
ersity hospital. All patients provided written informed consent to
articipate.
.2. Adenosine assay
Blood sampling was processed as described using laboratory-
repared tubes containing 3 ml of cold-stop solution composed of
nhibitors of degradation and red blood cell uptake of adenosine
36,39,41]. Samples were thenmaintained on ice until centrifugation.
fter deproteinization, adenosine was quantiﬁed by HPLC (Chrom-
ystems, Munich, Germany), adenosine being identiﬁed by its elution
ime and spectrum [39]. Measurement was made by comparison of
eak areas with those obtained using standards. The intra-assay and
nter-assay coefﬁcients of variation ranged from 1% to 3%.
.3. Incubation of Adonis with lymphocytes
Blood samples were collected from brachial vein into 8 ml tubes
ontaining sodium citrate/Ficoll (BD Vacutainer CPT, Beckton Dickin-
on, Franklin lakes, NJ). Peripheral blood mononuclear cells (PBMC)
ere prepared according to the manufacturer’s instructions. Viable
ell recovery was consistently over 98% with more than 95% of lym-
hocytes and less than 3% granulocytes. 0.25 × 106 cells were mixed
ith Adonis (0–1.2 μM in 1ml culturemedium), an IgMmAb directed
gainst a linear part of the second external loop of A2AR [35]. After
0 min incubation at room temperature under shaking, PBMC were
ither washed twice with phosphate-buffered saline, pH 7.3 for bind-
ng and A2AR expression tests or only centrifuged without washing
or functional test. Cell pellets were kept at −20 ◦C until use.
.4. Western blotting
To quantify both Adonis binding to lymphocytes and the lym-
hocyte A2AR expression, we used the Western blotting procedure
reviously described [42]. PBMC pellets previously incubated with or
ithout Adonis were lysed by a 3min sonication treatment at 47 kHz
ith the SDS–PAGE loading buffer containing 5% mercaptoethanol.
amples were then submitted to 12% SDS–PAGE analysis followed by
ransfer onto a PVDF membrane. Filters were incubated 20 min with
donis and thenwith horseradish peroxidase-labeled anti-mouse IgG
ab speciﬁc antibodies prior to chemiluminescent staining with Su-
erSignal West Femto (Pierce Biotechnology, Rockford, IL).In SDS–PAGE analysis in reducing condition, Adonis resolved in
heavy (65 kDa) and light (25 kDa) IgM chains bands. Quantiﬁcation of
Adonis bound to A2ARwas based on the detection of the light chain of
the IgM because it is readily detected by the labeled second antibody
directed partly to the light chain of Fab portion of mouse IgG shared
by mouse IgM. Densitometry analysis used ImageJ 1.42q (National
Institutes of Health, USA) and results from duplicates were expressed
as arbitrary units (AU) deﬁned as pixels of the light chain band versus
blot background.
The lymphocyte A2AR expression was similarly quantiﬁed except
that AUwere deﬁned as pixels of the canonical A2AR band versus blot
background. A2AR from PBMC not previously incubated with Adonis
migrated at 45 kDa and the corresponding band was detected by
Adonis binding during the Western blot procedure.
Adonis binding curves were established using six concentrations
of Adonis and non linear regression analysis were performed with a
one site speciﬁc binding equation Y = Bmax × X /(KD + X) using Prism
5 (GraphPad Software, Inc La Jolla, CA). Bmax expressed using the same
units as Y values and KD expressed using the same units as X values
were estimated for Adonis binding to each PBMC preparation.
2.5. cAMP test
The agonist properties of Adonis allow its use as a speciﬁc effec-
tor for cAMP production [35]. Brieﬂy, cellular cAMP measurement
was achieved on PBMC pellets incubated with Adonis by ELISA us-
ing the Amersham Biotrak Kit (GE healthcare Bio-Sciences, Upsala,
Sweden). Stimulation was stopped by adding dodecyltrimethylam-
moniumbromide acetate buffer. Results of duplicateswere expressed
as AU deﬁned as cAMP production generated in the presence versus
in the absence of Adonis. We examined the results obtained using
six concentrations of Adonis with Prism 5 (GraphPad Software) and
the sigmoidal dose–response curve: Y = Bottom + (Top − Bottom)/(1
+ 10[(Log EC50 − X) × Hill Slope ]). Top (Emax here) and Bottom are plateau
values in the units of Y and EC50 is the concentration of Adonis that
gives a response half way between Top and Bottom values. Hill slope
describes the steepness of the family of curves.
2.6. Statistical analysis
Quantitative variableswere expressedusingmeans ± SEM. Paired
t-test was used to compare KD and EC50 values and correlation tests
were made between adenosine, Bmax and Emax values. All the tests
were two-tailed and P-values less than 0.05were considered as statis-
tically signiﬁcant. Analyses were performed with Prism 5 (GraphPad
Software).
3. Results
3.1. Adenosine levels
The patients listed in Table 1 (7 women and 3 men; mean age: 52
years) were selected on the basis of NMS clinical symptoms. They had
APC ranging from 0.29 to 2.91 μM with a mean value ± SEM of 1.29
± 0.27 μM. As expected from the literature on NMS, most patients (7
out of 10) had higher APC than control subjects (0.20 to 0.70 μM; data
from the Biochemistry Laboratory of the Timone Hospital, Marseille,
France).
3.2. Saturation curves and dose–response curves
Adonis binding to PBMC from patients was assessed by Western
blotting visualizing the light chain of bound Adonis (Fig. 1(A)). Af-
ter densitometry analysis of the bands, the resulting Adonis binding
curves exhibited various plateau values ranging from3.05 to 68.13AU
(pixels of the light chain band versus blot background) with a mean
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Table 1
List of patients with results.
Patients Sex Age APC (μM) Bmax (AU) KD (μM) Emax (AU) EC50 (μM) A2AR (AU)
1 Female 62 1.55 63.14 0.12 22.57 0.48 19.56
2 Female 18 0.99 26.66 0.15 32 0.1 19.53
3 Female 39 2.37 68.13 0.09 16.5 0.08 32.02
4 Female 49 1.82 59.16 0.08 28.29 0.11 12.12
5 Female 74 0.77 27.33 0.33 34.62 0.36 6.41
6 Male 38 2.91 61.49 0.26 41.73 0.23 17.97
7 Male 62 0.29 12.39 0.42 49.89 0.09 8.69
8 Female 49 0.66 8.92 0.23 21.56 0.17 7.29
9 Female 52 1.01 3.05 0.08 31.57 0,11 9.24
10 Male 71 0.5 12.37 0.13 36 0.06 8.61
Mean 51.7 1.29 34.26 0.19 31.47 0.18 14.14
± SEM 5.43 0.27 8.18 0.04 3.14 0.04 2.56
Fig. 1. (A) Western blots of Adonis (25 kDa light chain) binding to PBMC from the 10
patients. For each patient, 6 doses of Adonis were tested in duplicate on separate gels
and one representative set of blots is shown. (B) Binding curves giving Bmax and KD
values. Curves derived from the pixel analysis of the Adonis light chain blots. (C) Dose–
response curves giving Emax and EC50 values for the 10 patients. For each set of curves,
2 representative curves are in black, the 8 other ones are in gray. Patient numbers are
at right of the curves. Results expressed in arbitrary units (AU) as deﬁned in Materials
and methods are means ± SD of duplicates. (D) Comparison of KD (black circles) and
EC50 (black squares) values interpolated from complete binding and dose–response
curves with Adonis. Results are expressed in μM. Each symbol with the corresponding
patient number represents individual mean value. Horizontal bars are means ± SEM
for the 10 patients.value ± SEM of 34.26 ± 8.18 AU (Fig. 1(B) and Table 1). Represen-
tative curves from Patients 1 and 2 were highlighted in black in Fig.
1 (B). Binding reached a plateau value at 63.14 AU of Adonis binding
for Patient 1 and at 26.66 AU for Patient 2, both patients exhibiting
similar KD value (0.12 and 0.15 μM, respectively; Table 1).
Adonis response curves for cAMP production also exhibited vari-
ous plateau values ranging from 16.50 to 49.89 AU (cAMP production
generated by Adonis versus basal cAMP level in the absence of Ado-
nis) with amean value ± SEM of 31.47 ± 3.14 AU (Fig. 1(C) and Table
1). Representative curves from Patients 9 and 3 were highlighted in
black in Fig. 1 (C). A maximal effect at 31.57 AU of cAMP production
was obtained for Patient 9 whereas only 16.5 AU were obtained for
Patient 3, both patients exhibiting similar EC50 values (0.11 and 0.08
μM, respectively; Table 1).
Fig. 1(D) shows that, taken as a whole, the distribution of KD and
EC50 values extrapolated from the above curves was not statistically
different: KD values ranged from 0.08 to 0.42 μM with a mean value
± SEM of 0.19 ± 0.04 μM and EC50 values ranged from 0.06 to 0.48
μM with a mean value ± SEM of 0.18 ± 0.04 μM. We noticed 2exceptions, Patient 7 displaying the highest KD (0.42 μM) had a 5-fold
lower EC50 (0.09μM) and, conversely, Patient 1 displaying the highest
EC50 (0.48 μM) had a 4-fold lower KD (0.12 μM) (Fig. 1(D) and Table
1).
3.3. Expression of A2AR
We found various lymphocyte A2AR expression levels with val-
ues ranging from 6.41 to 32.02 AU (pixels of the A2AR band versus
blot background) with a mean value ± SEM of 14.14 ± 2.56 AU.
Correlation studies were performed to compare lymphocyte A2AR ex-
pressions to APC, Bmax and Emax. Lymphocyte A2AR expressions were
found to be correlatedwith APC (Fig. 2(A)) and Bmax (Fig. 2(B)) but not
Emax (Fig. 2(C)) values. Once more, we noticed 2 exceptions: Patient 7
displaying the highest Emax (49.89 AU) had low A2AR level (8.69 AU)
while Patient 3 displaying the lowest Emax (16.5 AU) expressed the
highest A2AR level (32.02 AU).
4. Discussion
We found that Bmax of Adonis to A2AR varied from subject to sub-
ject whereas KD values were similar. Various Emax were also found
whereas the EC50 values were similar. More importantly, the KD val-
ues were found to be statistically not different from the EC50 values,
suggesting a lack of a reserve of receptors according to the criteria pre-
viously deﬁned. In 8 out of the 10 patients tested, the highest cAMP
production occurredwhen all the receptors were occupied by Adonis.
Results from 2 patients, however, illustrate opposite situations: Pa-
tient 7 exhibited a KD which was 5-fold higher than EC50, consistent
with the situation where a few occupied receptors produce a max-
imal effect (presence of spare receptors), and Patient 1 exhibited a
KD which was 4-fold lower than EC50, indicating a situation where a
low effect is obtained while all receptors are occupied. The latter case
suggests that many A2AR of this subject are not functional.
We also performed experiments to address the lymphocyte A2AR
expression usingWestern blotting. As previously reported in patients
with intradialytic hypotension during hemodialysis [43] and sponta-
neous and head-up-tilt-induced syncope [37,38], we found an over-
expression of lymphocyte A2AR which correlated with the increase in
APC and thereforewith themaximal level of Adonis binding. This sug-
gests that adenosine and A2AR are upregulated concomitantly and/
or interdependently. More intriguingly, lymphocyte A2AR expression
was generally not correlated with Emax suggesting a non linear re-
lation between the amount of receptors and their overall efﬁciency.
Therefore, adenosine appeared necessary but not sufﬁcient to modu-
late its immunosuppressive effect via theA2AR. Twopatients illustrate
opposite situations regarding Emax: Patient 7, previously suspected
with spare receptors, who expressed a few but highly efﬁcient recep-
tors and, conversely, Patient 3 who expressed high level of receptors
exhibiting low overall efﬁciency. The former, displaying a KD higher
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Fig. 2. Correlation study between lymphocyte A2AR expression levels and (A) APC,
(B) Bmax and (C) Emax. Results are expressed in μM for adenosine plasma levels and
arbitrary units (AU) as deﬁned in Materials and methods for A2AR expression, Bmax
and Emax levels. A2AR expressions were measured usingWestern blotting. Each symbol
represents individual mean value. Signiﬁcant correlation (P < 0.05) for the 10 patients
is indicated at right.
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ahan EC50, had probably some receptors engaged in an hyper-active
tate with an efﬁcient coupling to the effector (Gs for cAMP pro-
uction) whereas the latter, displaying a KD similar to EC50, likely
xpressed mostly inactive receptors, unmounted to cell-surface and
onstituting a putative reserve of intra-cellular standby receptors.
T-cells possess a T-cell receptor reserve to increase the ﬂexibility
f cell response to ligands of weaker potency [44]. Accordingly, we
uggest that a reserve of A2AR would promote cross-reactions with
ow afﬁnity ligands such as weak and partial agonists/antagonists.
onsequently, stimulating or blocking ligands other than adenosine
ould impede the ﬁne tuning of adenosine-induced immune regu-
ation by occupying more receptors to respond. However, absence of
pare receptors does not systematically mean that the amount of ex-
ressed A2AR on lymphocytes is the limiting factor to determine the
xtent of the effector response. Regarding the NMS situation, A2AR
re frequently over-expressed in peripheral lymphocytes and somepatients having a speciﬁc A2AR gene polymorphism express more re-
ceptors [45]. However, the resulting efﬁciency of the A2AR response
can also depend on the functional state of the receptors. The mul-
timerization process of G protein-coupled receptors [46] modulates
agonist efﬁciency when occupancy of a single receptor is needed to
obtain a full agonist action. For a recent example, TSH receptor signals
via activation of Gs to stimulate cAMP production when TSH binds to
one protomer of the TSH receptor homodimer [47]. Therefore, the
presence of spare receptors may also refer to the functional state of
the multimerized receptors.
Together, these data are consistent with a lack of spare A2AR on
lymphocytes as a general rule and their putative presence in some
patients appeared to be dependent on the functional state of the tar-
geted receptors. Therefore, the adenosinergic signaling efﬁciency in
lymphocytes likely involves many but not a few A2AR expressed on
lymphocytes and this is the amount and functional state of these
expressed receptors that determine the maximal level of the lym-
phocyte response to adenosine.
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